Individualizing Approaches To Surveillance Mammography In Older Breast Cancer Survivors - The I-MAMMO Study
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 26-002638
NCT ID: NCT07123649
Sponsor Protocol Number: 25-122
About this study
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Participant Inclusion Criteria:
* Women aged ≥ 80 years at the time of registration
* History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ \[because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible)
* No history of a recurrent breast cancer (i.e., a breast cancer that is deemed metastatic or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.
* Has at least one intact breast
* Has had mammogram screening/surveillance within the last 24 months
-≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
* No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy
* Ability and willingness to take surveys
* Receiving at least some of their oncology follow-up care at a participating site
* Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging
* If a patient required diagnostic breast testing in the past or at the time of the most recent mammogram AND the results were resolved to benign findings with no additional diagnostics recommended, they are eligible.
* If a patient's most recent mammogram result isn't yet available at the time of approach or study consent, the patient is eligible to proceed with consent and enrollment. If this mammogram then abnormal or requires additional imaging, that patient will not be included in the study analyses or surveys. This patient will be replaced.
Participant Exclusion Criteria:
* Inability to provide informed consent
* Assigned male sex at birth
* Breast or recent imaging findings requiring diagnostic testing at baseline
* Prior discontinuation of mammography by electronic medical record (EMR) review or patient report
* Prior atypical ductal hyperplasia (ADH) or non-pleomorphic LCIS only
* Psychiatric illness situations that would limit compliance with study requirements
* Those with metastatic breast cancer
* Those in hospice care
* Those whose clinician is not willing to participate
* Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults
Clinician Inclusion Criteria:
* Must be an active clinician (MD, NP, or PA) at a participating institution
* Sees at least one breast-cancer survivor aged ≥ 80
* Clinician must be able to read, speak, and write in English
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 12/22/2025. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Kathryn Ruddy, M.D. |
Open for enrollment |
|
More information
Publications
Publications are currently not available